Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat
Nathalie Lapointe, MSc*,
Charles Blais, Jr, PhD ,
Albert Adam, PhD,
Thomas Parker, MD, FACC*,
Martin G. Sirois, PhD ,
Hugues Gosselin, DT,
Robert Clément, BSc and
Jean L. Rouleau, MD, FACC*,*
* Division of Cardiology, University Health Network, Toronto General Hospital, Toronto, Ontario Canada
Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada
Department of Medicine, Montreal Heart Institute, Montreal, Quebec, Canada
View larger version (31K):
[in a new window]
|
Figure 1 Flow diagram of various groups of rats according to the presence of myocardial infarction (MI) and treatment group. All rats were randomized 4 h after coronary artery ligation. The MI size was determined at the end of the study, and, thereafter, the rats were classified according to their MI size.
|
|
View larger version (28K):
[in a new window]
|
Figure 2 Left ventricle pressure-volume relations according to myocardial infarction (MI) size and treatment group. BMI = large MI.
|
|
|
) (A), transforming growth factor-beta (TGF-ß1) (B) and interleukin-10 (IL-10) (C) messenger ribonucleic acid (mRNA) expression in the left ventricle 56 days after induction of a moderate-to-large myocardial infarction (MI) or after sham-to-small operation. Drug treatments (omapatrilat 40 mg/kg/day [OMA-40] and captopril 160 mg/kg/day [CAP-160]) were started 4 h after coronary artery ligation. Values are means ± SEM of seven to nine animals in each group. Values (Cytokine-to-glyceraldehyde-3-phosphate dehydrogenase [GAPDH] ratio, derived from RT-PCR) are arbitrary scanning units normalized to sham group = 1. *p < 0.05 vs. sham-to-small;